Literature DB >> 6320486

Effect of neutral proteases from blood leukocytes on human platelets.

K Bykowska, J Kaczanowska, M Karpowicz, J Stachurska, M Kopeć.   

Abstract

Two highly purified neutral proteases from human leukocytes i.e. elastase-like protease (ELP) and chymotrypsin-like protease (CLP) do not destroy human platelets since no difference was found in 51Cr liberation from control and enzyme-treated platelets. As with pancreatic chymotrypsin (alpha-CT) ELP does not induce the release of 3H-serotonin while CLP provokes 3H-serotonin secretion, in an enzyme concentration and time dependent fashion. The rate and degree of 3H-serotonin release by CLP is similar to that produced by thrombin. Incubation of platelets at 37 degrees C for 30 min with alpha-CT or ELP renders them resistant to thrombin-releasing activity. Thrombin did not liberate any additional label from platelets which lost over 60% of serotonin during the preceding incubation with CLP. alpha-CT and ELP do not aggregate platelets either in the presence or absence of apyrase. CLP does aggregate platelets suspended in Tyrode buffer without apyrase but not in the presence of apyrase (100 mg/l). The action of alpha-CT, ELP and CLP on washed platelets induces a progressive prolongation of lag phase and a decrease in changes of light transmission during aggregation by thrombin. Similarly to alpha-CT-treated platelets, those subjected to CLP action aggregate in the presence of human fibrinogen. It is concluded that: (1) neutral proteases possibly contribute to development of defects in platelet function in pathological states associated with liberation of leukocyte content into the circulation, (2) CLP similarly to alpha-CT, exposes fibrinogen receptors but in contrast to alpha-CT, CLP aggregates platelets and stimulates serotonin secretion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6320486

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  Bidirectional modulation of platelet and polymorphonuclear leukocyte activities.

Authors:  A Del Maschio; E Dejana; G Bazzoni
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

2.  NPC 15669, an Antiinflammatory Leucine Derivative, Reduces In Vitro Platelet Aggregability in Both Swine and Human Plasma.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Intracellular Ca2+ rise in human platelets induced by polymorphonuclear-leucocyte-derived cathepsin G.

Authors:  M Molino; M Di Lallo; G de Gaetano; C Cerletti
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

4.  Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin).

Authors:  M Chignard; M A Selak; J B Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

5.  Neutrophil proteinase cathepsin G is proteolytically active on the human platelet glycoprotein Ib-IX receptor: characterization of the cleavage sites within the glycoprotein Ib alpha subunit.

Authors:  D Pidard; P Renesto; M C Berndt; S Rabhi; K J Clemetson; M Chignard
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

6.  Cathepsin G is a strong platelet agonist released by neutrophils.

Authors:  M A Selak; M Chignard; J B Smith
Journal:  Biochem J       Date:  1988-04-01       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.